Search Reports:

Enter company name or symbol or keyword from report title or report description. You can also use our advanced search option to further filter your results.

Accuracy of Opinions

989 (79%) - Correct
261 (21%) - Incorrect

Explanation

Recent News on Covered Stocks
Release of final Phase III trial data of a small cap company's tissue disorder drug expected in May - June 2012
Read Report  See Other Upcoming Events

Trading Ideas

Big Troubles for Biotech Big Pharma

Not just a Fat Issue

Read Report See More Reports>>
 
 

Commentary

Review the Top 10 Small Cap Biotech performers over the last month and their Drivers. This report lists the companies, their stock performance over the last month and some drivers that have contributed to the rise in the stock price. (April 7, 2010 through May 7, 2010)

Read Report

Biotech Stocks Performance Table – 2009: Lists over 250 Biotechnology companies and their stock performance for 2009 (Quarterly and Annually).

Read Report See More Reports>>

Upcoming Event Reports

Celldex Therapeutics, Inc. (CLDX) - CDX-011 for Heavily Pretreated Metastatic or Locally Advanced GPNMB-positive Breast Cancer (Phase IIb trial)
Event Date - May 23, 2012 - PDF - Price: $20.00
Add to cart    View Report

Progenics Pharmaceuticals, Inc. (PGNX) - Relistor for Opioid-Induced Constipation (OIC) in Non-Cancer Chronic Pain (FDA Approval)
Event Date - April 27, 2012 - PDF - Price: $20.00
Add to cart    View Report

Protalix BioTherapeutics, Inc. (PLX) - Taliglucerase alfa for Gaucher Disease (CHMP Review)
Event Date - April 2012 - PDF - Price: $20.00
Add to cart    View Report

VIVUS Inc. (VVUS) - Qnexa for Obesity (FDA Approval 2nd Attempt)
Event Date - June 2012 - PDF - Price: $20.00
Add to cart    View Report

Anthera Pharmaceuticals, Inc. (ANTH) - Blisibimod for Systemic Lupus Erythematosus/SLE (Phase IIb PEARL-SC trial)
Event Date - - PDF - Price: $20.00
Add to cart    View Report

See More Reports>>
 

Performance of Upcoming Events
Year New BioMedicine * S & P 500 NASDAQ
2005 44.87% -0.11% 2.47%
2006 48.51% 14.89% 7.64%
2007 40.36% 6.34% 9.46%
2008 8.90% -33.84% -40.54%
2009 63.89% 23.49% 43.72%
2010 49.01% 12.64% 15.62%
*For the methodology of the performance calculation, please contact: kpaul@newbiomedicine.com See Other Performances

Event Calendars   See Description of Calendars

All Upcoming Events In Biotechnology - May 7, 2012
- Price: $80
Add to Cart

30 Upcoming Events Without Opinion - May 7, 2012
- Price: $10
Add to Cart

30 Upcoming Events With Opinion - May 7, 2012
- Price: $300
Add to Cart

New BioMedicine Top 10 Gainers - February 20, 2010
- Price: $10
Add to Cart

New BioMedicine Top 10 Losers - February 20, 2010
- Price: $10
Add to Cart

Click here to download Adobe Reader

Sample Report:

VRTX's HCV drug Telaprevir received FDA approval on May 23, 2011. New BioMedicine had issued a report on this event on May 3, 2011. To read more about the drug, the disease, the market, the competition, etc. access it at the link below.
 

Basket Reports:

Free Basket Reports

Specific theme-based reports at a value price
View Package

©Copyright 2012 New Bio Medicine, LLC. All Right Reserved.